SEOUL – South Korea’s Daewoong Pharmaceutical Co. Ltd. has signed a licensing deal with Seltek for the approval and commercialization in Turkey of Nabota (botulinum toxin), a drug administered via injection to improve the frown lines by weakening or paralyzing certain muscles or nerves.
Daewoong Strikes New Deal For Botox Rival
After a past deal with Evolus to sell the product in the U.S. and Europe, Daewoong is searching for other markets in Asia and Latin America for its Botox competitor, and has just linked up with Turkey's Seltek.
More from South Korea
More from Focus On Asia
Novotech's CEO talks about rising interest for trials in regions with “regulatory agility” and “strategic insulation” from geopolitical complexity, especially among emerging and mid-sized biotech sponsors. Operational "reassessment” among some sponsors on exposure to China-based CROs/CRDMOs is another area he discussed.
Akeso’s penpulimab will be the second to hit the US market for nasopharyngeal carcinoma, but the first to win FDA approval for the indication based on clinical findings in US patients.
Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.